🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

RecruitingPhase 2Ages 18 Years - anyAllStanford University
NCT06824454 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult kidney transplant patients. * No known contraindications to Dipyridamole Exclusion Criteria: * Contraindications to Dipyridamole. * Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation). * Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.
💊

What it tests

  • Dipyridamole 75 MG
📍

Where

1 site
Stanford University
Stanford, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy